【摘要】 目的 觀察光子嫩膚合并左旋維生素C導入治療面部黃褐斑的臨床療效。 方法 2008年3月-2009年5月，105例黃褐斑患者隨機分為兩組，治療組53例，用光子嫩膚治療2個療程后用左旋維生素C導入，1次/周，持續2個月；對照組52例，單純使用光子嫩膚治療后進行防曬、護膚治療2個月。 結果 治療組有40例黃褐斑消失，13例色斑明顯減淡；對照組有12例黃褐斑消失，26例色斑明顯減淡，11例色斑減淡，3例無效。兩組療效比較，差異有統計學意義（Plt;0.05）。 結論 光子嫩膚合并左旋維生素C導入治療面部黃褐斑安全、方便、療效好，患者易于接受。【Abstract】 Objective To observe the clinical efficacy of the treatment of facial melasma by intense pulsed light (IPL) photorejuvenation combined with vitamin C. Methods From March 2008 to May 2009, 105 patients with facial melasma were randomly divided into two groups. In the treatment group, there were 53 patients who were treated with vitamin C after IPL photorejuvenation once a week for two months. For the 52 patients in the control group, sunscreen and skin care treatment were carried out after IPL treatment for two months. Results In the treatment group, 40 patients’ melasma disappeared and 13 patients’ melasma dodged obviously. In the control group, 12 patients’ melasma disappeared and pigmentation existed more or less in 40 patients. Conclusion Treatment for facial melasma by IPL photorejuvenation combined with vitamin C is safe, convenient, and have good effect, which can be easily accepted by the patients.
Effective symptom management can alleviate the physical and psychological distress experienced by patients with cancer, improve quality of life, and contribute to treatment adherence and improve clinical outcomes. However, most existing guidelines are developed for healthcare professionals, and patients and the public have limited access to standardized and comprehensible guidance on symptom management. To address this gap and to facilitate effective communication and shared decision-making, this study proposes the development of a patient version of the cancer symptom management guideline. The development process will adhere to the methodological framework recommended by the Guidelines International Network and the World Health Organization. The GRADE approach will be employed to assess the certainty of evidence and to formulate recommendations. In addition, the process will be informed by the Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ) instrument and the Reporting Items for Practice Guidelines in Healthcare-Public or Patient Versions of Guidelines (RIGHT-PVG). This protocol outlines the establishment of the guideline working group, the identification and prioritization of key questions, evidence retrieval and appraisal, and the formulation of recommendations, with the aim of ensuring methodological rigor and transparency in the development of the patient guideline and providing methodological reference for similar guideline initiatives.